Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from EUDA Health Holdings ( (EUDA) ).
On August 26, 2025, EUDA Health Holdings Limited announced that its subsidiary, EUDA Health Pte. Ltd., has secured exclusive worldwide distribution rights for a next-generation immune health supplement from Chemokine Pte. Ltd. This supplement, marketed under the brand name Euda Helixé, will initially be available in Singapore, Malaysia, and China, with plans for future market expansion. The supplement utilizes cutting-edge epigenetic technology to enhance metabolism, boost vitality, and support longevity, reinforcing EUDA’s wellness product portfolio. This strategic move positions EUDA at the forefront of molecular precision wellness, leveraging breakthrough gene activation technology, and is expected to diversify revenue streams with projected sales of 500,000 bottles over the next 12 months.
The most recent analyst rating on (EUDA) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on EUDA Health Holdings stock, see the EUDA Stock Forecast page.
More about EUDA Health Holdings
EUDA Health Holdings Limited is a Singapore-based leading non-invasive healthcare provider in Asia, focusing on markets in Singapore, Malaysia, and China. The company aims to become a market leader in non-invasive and preventive healthcare, particularly in the fast-growing longevity sector, addressing the healthcare needs of over 1.8 billion people in the region. EUDA also operates a property management business in Singapore.
Average Trading Volume: 76,792
Technical Sentiment Signal: Sell
Current Market Cap: $99.21M
For detailed information about EUDA stock, go to TipRanks’ Stock Analysis page.